The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
The emerging field of oncolytic virus-based cancer immunotherapy
Open accessAbstract
Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with cancers resistant to traditional therapies. Natural or genetically modified OVs are multifaceted tumor killers. They directly lyse tumor cells while sparing normal cells, and indirectly potentiate anti-tumor immunity by releasing antigens and activating inflammatory responses in the tumor microenvironment (TME). However, some limitations, such as penetration of OVs into tumors and the hosts’ antiviral immune response, are impeding the application of oncolytic virotherapy’s broad translation into the clinic. If these challenges can be overcome, combination therapies, such as OVs plus immune checkpoint blockades (ICBs), chimeric antigen receptor (CAR) T cells, or CAR natural killer (NK) cells, will provide powerful therapeutic platforms in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Gasdermin E suppresses tumour growth by activating anti-tumour immunity
Zhang, Z., Zhang, Y., Xia, S., Kong, Q., Li, S., Liu, X., Junqueira, C., Meza-Sosa, K. F., Mok, T. M. Y., Ansara, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2071-9 · Cited by 1,686
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Aboody, K. S., Brown, A., Rainov, N. G., Bower, K. A., Liu, S., Yang, W., Small, J. E., Herrlinger, U., Ourednik, V., Black, P. M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12846 · Cited by 1,207
Studeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., Champlin, R. E., & Andreeff, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh299 · Cited by 842
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01124 · Cited by 825
Chesney, J., Puzanov, I., Collichio, F., Singh, P., Milhem, M. M., Glaspy, J., Hamid, O., Ross, M., Friedlander, P., Garbe, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7379 · Cited by 631
Saha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Xia, T., Konno, H., Ahn, J., & Barber, G. N. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.029 · Cited by 589
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway
Lau, L., Gray, E. E., Brunette, R. L., & Stetson, D. B. (2015) · Science · doi:10.1126/science.aab3291 · Cited by 453
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Self-citationOncolytic viruses as engineering platforms for combination immunotherapy
Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C., & Nelson, B. H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0009-4 · Cited by 417
Tang, X., Yang, L., Li, Z., Nalin, A. P., Dai, H., Xu, T., Yin, J., You, F., Zhu, M., Shen, W., et al. (2018) · Europe PMC (PubMed Central) · Cited by 406
Self-citationPecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
Xia, T., Konno, H., & Barber, G. N. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1404 · Cited by 383
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Self-citationIkeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339
Self-citationTalimogene laherparepvec: First in class oncolytic virotherapy
Conry, R. M., Westbrook, B., McKee, S., & Norwood, T. G. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412896 · Cited by 335
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040557897 · Cited by 332
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
Friedman, G. K., Johnston, J. M., Bag, A. K., Bernstock, J. D., Li, R., Aban, I., Kachurak, K., Nan, L., Kang, K.-D., Totsch, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024947 · Cited by 328
Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Liang, M. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666171129221503 · Cited by 314
Andtbacka, R. H. I., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A., Amatruda, T., Zager, J. S., Cranmer, L., Hsueh, E., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5286-0 · Cited by 308
Antonio Chiocca, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc948 · Cited by 306
Xia, Z.-J., Chang, J.-H., Zhang, L., Jiang, W.-Q., Guan, Z.-Z., Liu, J.-W., Zhang, Y., Hu, X.-H., Wu, G., Wang, H.-Q., et al. (2004) · PubMed · Cited by 302
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
Pérez‐Larraya, J. G., García-Moure, M., Labiano, S., Patiño‐García, A., Dobbs, J., González-Huarriz, M., Zalacaín, M., Marrodán, L., Martínez-Vélez, N., Puigdelloses, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202028 · Cited by 300
Natural killer cell homing and trafficking in tissues and tumors: from biology to application
Ran, G. H., Lin, Y. Q., Tian, L., Zhang, T., Yan, D. M., Yu, J. H., & Deng, Y. C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01058-z · Cited by 282
Self-citationResistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors
Park, A. K., Fong, Y., Kim, S.-I., Yang, J., Murad, J. P., Lu, J., Jeang, B., Chang, W.-C., Chen, N. G., Thomas, S. H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1863 · Cited by 271
Kambara, H., Okano, H., Chiocca, E. A., & Saeki, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3227 · Cited by 263
Self-citationPhuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S. M., TenEyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J., & Galanis, E. (2003) · PubMed · Cited by 248
Chen, X., Han, J., Chu, J., Zhang, L., Zhang, J., Chen, C., Chen, L., Wang, Y., Wang, H., Yi, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8526 · Cited by 242
Self-citationAntitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Gujar, S., Pol, J. G., Kim, Y., Lee, P. W., & Kroemer, G. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 231
Ma, R., Lu, T., Li, Z., Teng, K.-Y., Mansour, A. G., Yu, M., Tian, L., Xu, B., Ma, S., Zhang, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0035 · Cited by 221
Self-citationKillers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S. T., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 217
Evgin, L., Kottke, T., Tonne, J., Thompson, J., Huff, A. L., van Vloten, J., Moore, M., Michael, J., Driscoll, C., Pulido, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn2231 · Cited by 208
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Alvarez-Breckenridge, C. A., Yu, J., Price, R., Wojton, J., Pradarelli, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.3013 · Cited by 205
Self-citationMa, J., Ramachandran, M., Jin, C., Quijano-Rubio, C., Martikainen, M., Yu, D., & Essand, M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2236-3 · Cited by 196
Park, S. H., Breitbach, C. J., Lee, J., Park, J. O., Lim, H. Y., Kang, W. K., Moon, A., Mun, J.-H., Sommermann, E. M., Maruri‐Avidal, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.109 · Cited by 195
Oncolytic viruses: a novel form of immunotherapy
Prestwich, R. J., Harrington, K. J., Pandha, H. S., Vile, R. G., Melcher, A. A., & Errington, F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1581 · Cited by 180
Galanis, E., Atherton, P. J., Maurer, M. J., Knutson, K. L., Dowdy, S. C., Cliby, W. A., Haluska, P., Long, H. J., Oberg, A., Aderca, I., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2533 · Cited by 179
Qiao, J., Wang, H., Kottke, T., White, C., Twigger, K., Diaz, R. M., Thompson, J., Selby, P., de Bono, J., Melcher, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1510 · Cited by 174
Maraba Virus as a Potent Oncolytic Vaccine Vector
Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S., Chen, L., Kazdhan, N., Bramson, J. L., Stojdl, D. F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.249 · Cited by 173
T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
Yu, F., Wang, X., Guo, Z. S., Bartlett, D. L., Gottschalk, S. M., & Song, X.-T. (2014) · Molecular Therapy · doi:10.1038/mt.2013.240 · Cited by 170
Dispenzieri, A. A., Tong, C., LaPlant, B. R., Lacy, M. Q., Laumann, K. M., Dingli, D., Zhou, Y., Federspiel, M. J., Gertz, M. A., Hayman, S. R., et al. (2017) · Leukemia · doi:10.1038/leu.2017.120 · Cited by 170
Cerullo, V., Diaconu, I., Kangasniemi, L., Rajecki, M., Escutenaire, S., Koski, A., Romano, V., Rouvinen, N., Tuuminen, T., Laasonen, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.113 · Cited by 159
The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Hingorani, M., Spitzweg, C., Vassaux, G., Newbold, K. L., Melcher, A. A., Pandha, H., Vile, R. G., & Harrington, K. J. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054194 · Cited by 156
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Fajardo, C. A., Guedan, S., Rojas, L. A., Moreno, R., Arias-Badia, M., de Sostoa, J., June, C. H., & Alemany, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1708 · Cited by 155
Trained ILC3 responses promote intestinal defense
Serafini, N., Jarade, A., Surace, L., Gonçalves, P., Sismeiro, O., Varet, H., Legendre, R., Coppée, J., Disson, O., Durum, S. K., et al. (2022) · Science · doi:10.1126/science.aaz8777 · Cited by 155
Oncolytic viruses: From bench to bedside with a focus on safety
Buijs, P., Verhagen-Oldenampsen, J., van Eijck, C. H. J., & van den Hoogen, B. G. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1037058 · Cited by 153
Kowalsky, S. J., Liu, Z., Feist, M., Berkey, S. E., Ma, C., Ravindranathan, R., Dai, E., Roy, E. J., Guo, Z. S., & Bartlett, D. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.013 · Cited by 152
Expression and function of chemokine receptors in human multiple myeloma
Möller, C., Strömberg, T., Juremalm, M., Nilsson, K., & Nilsson, G. P. (2003) · Leukemia · doi:10.1038/sj.leu.2402717 · Cited by 148
Kaufman, H. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24624 · Cited by 146
Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
Li, J., O’Malley, M. E., Urban, J. A., Sampath, P., Guo, Z. S., Kaliński, P., Thorne, S. H., & Bartlett, D. L. (2011) · Molecular Therapy · doi:10.1038/mt.2010.312 · Cited by 139
Havunen, R., Siurala, M., Sorsa, S., Grönberg-Vähä-Koskela, S. A. M., Behr, M., Tähtinen, S., Santos, J. M., Karell, P., Rusanen, J., Nettelbeck, D. M., et al. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.12.004 · Cited by 136
Passaro, C., Alayo, Q. A., DeLaura, I. F., McNulty, J., Grauwet, K., Ito, H., Bhaskaran, V., Mineo, M., Lawler, S. E., Shah, K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2311 · Cited by 136
Self-citationHarrington, K. J., Puzanov, I. J., Hecht, J. R., Hodi, F. S., Szabó, Z. R., Murugappan, S., & Kaufman, H. L. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1115725 · Cited by 134
Oncolytic virotherapy as immunotherapy
Melcher, A., Harrington, K., & Vile, R. (2021) · Science · doi:10.1126/science.abk3436 · Cited by 133
Oncolytic viruses: overcoming translational challenges
Martínez‐Quintanilla, J., Seah, I. Y. J., Chua, M. M. J., & Shah, K. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122287 · Cited by 130
Xu, B., Tian, L., Chen, J., Wang, J., Ma, R., Dong, W., Li, A., Zhang, J., Chiocca, E. A., Kaur, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26003-6 · Cited by 124
Self-citationKansler, E. R., Dadi, S., Krishna, C., Nixon, B. G., Stamatiades, E. G., Liu, M., Kuo, F., Zhang, J., Zhang, X., Capistrano, K. J., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01213-2 · Cited by 121
Chan, W. K., Kang, S., Youssef, Y., Glankler, E. N., Barrett, E. R., Carter, A. M., Ahmed, E. H., Prasad, A., Chen, L., Zhang, J., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0649 · Cited by 120
Self-citationTargeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors
Speck, T., Heidbuechel, J. P. W., Veinalde, R., Jaeger, D., Kalle, C. V., Ball, C. R., Ungerechts, G., & Engeland, C. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2651 · Cited by 119
Oncolytic viruses: finally delivering
Seymour, L. W., & Fisher, K. D. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.481 · Cited by 118
Ahmed, A. U., Thaçi, B., Tobias, A. L., Auffinger, B., Zhang, L., Cheng, Y., Kim, C. K., Yunis, C., Han, Y., Alexiades, N. G., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt141 · Cited by 115
Muthana, M., Rodrigues, S., Chen, Y., Welford, A. F., Hughes, R., Tazzyman, S. J., Essand, M., Morrow, F. J., & Lewis, C. E. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3056 · Cited by 107
Mazzacurati, L., Marzulli, M., Reinhart, B., Miyagawa, Y., Uchida, H., Goins, W. F., Li, A., Kaur, B., Caligiuri, M. A., Cripe, T. P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.177 · Cited by 104
Self-citationJochéms, C., Tucker, J. A., Tsang, K.-Y., Madan, R. A., Dahut, W. L., Liewehr, D. J., Steinberg, S. M., Gulley, J. L., & Schlom, J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1524-0 · Cited by 100
TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response
Han, J., Chen, X., Chu, J., Xu, B., Meisen, W. H., Chen, L., Zhang, L., Zhang, J., He, X., Wang, Q.-E., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0894 · Cited by 98
Self-citationAlvarez-Breckenridge, C. A., Yu, J., Price, R. L., Wei, M., Wang, Y., Nowicki, M. O., Ha, Y. P., Bergin, S. M., Hwang, C., Fernández, S., et al. (2012) · Journal of Virology · doi:10.1128/jvi.05545-11 · Cited by 96
Self-citationAn oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma
Xu, B., Ma, R., Russell, L., Yoo, J. Y., Han, J., Cui, H., Yi, P., Zhang, J., Nakashima, H., Dai, H., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4302 · Cited by 92
Self-citationA Randomized, Controlled Trial of an Aerosolized Vaccine against Measles
Low, N. N., Bavdekar, A., Jeyaseelan, L., Hirve, S. S., Ramanathan, K., Andrews, N. J., Shaikh, N., Jadi, R., Rajagopal, A., Brown, K. E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407417 · Cited by 88
Tian, L., Xu, B., Teng, K.-Y., Song, M., Zhu, Z., Chen, Y., Wang, J., Zhang, J., Feng, M., Kaur, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1248 · Cited by 83
Self-citationZhang, H., Xie, W., Zhang, Y., Dong, X., Liu, C., Yi, J., Zhang, S., Wen, C., Zheng, L., & Wang, H. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00389-3 · Cited by 81
First Oncolytic Viral Therapy for Melanoma
Poh, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-nb2015-158 · Cited by 79
Jung, K. H., Choi, I.-K., Lee, H., YAN, H. H., Son, M. K., Ahn, H. M., Hong, J., Yun, C., & Hong, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.009 · Cited by 79
Oncolytic measles virus strains as novel anticancer agents
Msaouel, P., Opyrchal, M., Domingo‐Musibay, E., & Galanis, E. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.749851 · Cited by 76
Cytokines in oncolytic virotherapy
Pol, J. G., Workenhe, S. T., Konda, P., Gujar, S. A., & Kroemer, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.007 · Cited by 75
Tähtinen, S., Grönberg-Vähä-Koskela, S. A. M., Lumén, D., Merisalo-Soikkeli, M., Siurala, M., Airaksinen, A. J., Vähä-Koskela, M. J. V., & Hemminki, A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0220-t · Cited by 72
Saha, D., Wakimoto, H., Peters, C. W., Antoszczyk, S. J., Rabkin, S. D., & Martuza, R. L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1717 · Cited by 71
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Groeneveldt, C., van Hall, T., van der Burg, S. H., ten Dijke, P., & van Montfoort, N. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.003 · Cited by 71
Chen, L., Chen, H., Ye, J., Ge, Y., Wang, H., Dai, E., Ren, J., Liu, W., Ma, C., Ju, S., et al. (2021) · Theranostics · doi:10.7150/thno.56494 · Cited by 69
Sugawara, K., Iwai, M., Yajima, S., Tanaka, M., Yanagihara, K., Seto, Y., & Todo, T. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.022 · Cited by 65
Advances in Oncolytic Virus Therapy for Glioma
Haseley, A., Alvarez-Breckenridge, C. A., Chaudhury, A. R., & Kaur, B. (2008) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909787002573 · Cited by 64
Jung, B., Oh, E., Hong, J., Lee, Y., Park, K. D., & Yun, C. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.009 · Cited by 62
Bridle, B. W., Clouthier, D., Zhang, L., Pol, J. G., Chen, L., Lichty, B. D., Bramson, J. L., & Wan, Y. (2013) · OncoImmunology · doi:10.4161/onci.26013 · Cited by 61
Pisklakova, A., McKenzie, B., Zemp, F. J., Lun, X. Q., Kenchappa, R. S., Etame, A. B., Rahman, M. M., Reilly, K. M., Pilon‐Thomas, S., McFadden, G., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now006 · Cited by 58
Dey, M., Yu, D., Kanojia, D., Li, G., SUKHANOVA, M. J., Spencer, D. A., Pituch, K. C., Zhang, L., Han, Y., Ahmed, A. U., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.024 · Cited by 58
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
Saha, D., Rabkin, S. D., & Martuza, R. L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000345 · Cited by 56
Otani, Y., Yoo, J. Y., Chao, S., Liu, J. N., Jaime‐Ramirez, A. C., Lee, T. J., Hurwitz, B. S., Yan, Y., Dai, H., Glorioso, J. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3420 · Cited by 52
Self-citationILC1s control leukemia stem cell fate and limit development of AML
Li, Z., Ma, R., Ma, S., Tian, L., Lu, T., Zhang, J., Mundy-Bosse, B. L., Zhang, B., Marcucci, G., Caligiuri, M. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01198-y · Cited by 49
Self-citationSette, P., Amankulor, N. A., Li, A., Marzulli, M., Leronni, D., Zhang, M., Goins, W. F., Kaur, B., Bolyard, C. M., Cripe, T. P., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.10.005 · Cited by 48
Self-citationGhonime, M. G., & Cassady, K. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0014 · Cited by 47
Cervera-Carrascón, V., Quixabeira, D. C. A., Havunen, R., Santos, J. M., Kutvonen, E., Clubb, J. H. A., Siurala, M., Heiniö, C., Zafar, S., Koivula, T. T., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.003 · Cited by 47
Eckert, E. C., Nace, R. A., Tonne, J. M., Evgin, L., Vile, R. G., & Russell, S. J. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.003 · Cited by 43
Simpson, G. R., Horvath, A. A., Annels, N. E., Pencavel, T. D., Metcalf, S., Seth, R., Peschard, P., Price, T., Coffin, R. S., Mostafid, H. A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.577 · Cited by 34
Nounamo, B., Liem, J., Cannon, M. J., & Liu, J. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.08.002 · Cited by 34
A T-cell engager-armed oncolytic vaccinia virus to target the tumor stroma
Song, X., Feng, Y., & Hong, B. (2017) · Cancer translational medicine · doi:10.4103/ctm.ctm_13_17 · Cited by 30
Lucia, M. D., Cotugno, G., Bignone, V., Garzia, I., Nocchi, L., Langone, F., Petrovic, B., Sasso, E., Pepe, S., Froechlich, G., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.10.006 · Cited by 30
Dimitriou, F., Hauschild, A., Mehnert, J. M., & Long, G. V. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351123 · Cited by 30
Liu, W., Wang, X., Feng, X., Yu, J., Liu, X., Jia, X., Zhang, H., Wu, H., Wang, C., Wu, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215661 · Cited by 22
Self-citationRavirala, D., Mistretta, B., Gunaratne, P. H., Pei, G., Zhao, Z., & Zhang, X. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002454 · Cited by 15
Nakashima, H., & Chiocca, E. A. (2013) · Journal of Virology · doi:10.1128/jvi.02668-13 · Cited by 12
Self-citationModification of HSV-1 to an Oncolytic Virus
Nakashima, H., & Chiocca, E. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0428-0_8 · Cited by 11
Self-citation
Cited by
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Metadata
- Authors
- Ma, R., Li, Z., Chiocca, E. A., Caligiuri, M. A., & Yu, J.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 9
- Issue
- 2
- Pages
- 122-139
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W4309438509
- Cited by
- 318
- References
- 108
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.